Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
|Articles|January 1, 2000
Oncology NEWS International
- Oncology NEWS International Vol 9 No 1
- Volume 9
- Issue 1
NCI Seeks Toxicity Studies of Five Natural Substances
RESEARCH TRIANGLE PARK, NC—The National Toxicology Program is considering an NCI request that it do toxicity studies of four herbal products and a substance found in vegetables: aloe vera, used in cosmetics and as a dietary supplement; ginseng, promoted to increase vigor; kava kava, sold as a mood elevator; milk thistle, believed by some to prevent cancer and protect the liver; and indole-3-carbinol, which occurs in cruciferous
Advertisement
RESEARCH TRIANGLE PARK, NCThe National Toxicology Program is considering an NCI request that it do toxicity studies of four herbal products and a substance found in vegetables: aloe vera, used in cosmetics and as a dietary supplement; ginseng, promoted to increase vigor; kava kava, sold as a mood elevator; milk thistle, believed by some to prevent cancer and protect the liver; and indole-3-carbinol, which occurs in cruciferous vegetables, and, according to some evidence, may reduce cancer risk.
Articles in this issue
almost 27 years ago
New Strategies for Treating Ovarian Canceralmost 27 years ago
Researchers See More Effective Lung Cancer Screening, Therapyalmost 27 years ago
Goserelin Reduces Breast Ca Recurrence in Younger Womenalmost 27 years ago
ODAC Recommends Approval of Targretin for Advanced CTCLalmost 27 years ago
IOM Assessing Early Breast Cancer Detection Technologiesalmost 27 years ago
CRFA Honors Three With Its 1999 FrontLine Awardsalmost 27 years ago
Aromasin, New Hormonal Agent, Approved for Breast Canceralmost 27 years ago
LEDs Developed by NASA Used to Ablate Brain Tumorsalmost 27 years ago
Early Androgen Deprivation Beneficialalmost 27 years ago
Higher-Dose RT May Improve Prostate Cancer OutcomeAdvertisement
Related to this article
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in nonpalpable breast cancer.
ASCENT-03 subgroup data show sacituzumab govitecan improved PFS vs chemotherapy across subgroups in untreated metastatic TNBC.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Bispecific antibodies targeting PD-L1 showed activity across first-, second-, and later-line advanced neuroendocrine carcinoma in 3 trials presented at ESMO 2026.
Petosemtamab plus pembrolizumab cut the risk of death by 50% vs pembrolizumab alone in first-line recurrent or metastatic PD-L1–positive head and neck cancer.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
The phase 3 IMpactMF study will be discontinued after an independent committee determined it was unlikely to meet its primary end point of overall survival.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Plus Chemo Improves PFS in PD-L1+ HR+/HER2– Breast Cancer
2
New ASTRO Guideline Backs Hypofractionated Radiation in Prostate Cancer
3
CEA-High Expression Shows Early Promise as a Biomarker for BG-C477 in NSCLC
4
Adapting Stereotactic Radiation to Treatment Response in Metastatic RCC
5